Health Canada has approved Ozempic to reduce the risk of kidney deterioration in type 2 diabetes patients.
• Read also: Ozempic: American restaurateurs offer “children’s menus” to under -medication customers
Between 30 % and 50 % of people with type 2 diabetes develop one or another of chronic kidney disease.
An international clinical trial, called Flow, has shown that the risk of significant deterioration or renal failure was 24% lower in patients taking ozempic compared to those receiving placebo injection.
Patients taking this medication were also less likely to die from a cardiovascular disease, another condition that affects many diabetic patients.
The study, funded by Novo Nordisk, manufacturer of Ozempic, was evaluated by peers and published in the New England Journal of Medicine Last year, and contributed to Health Canada’s decision.
The Dr David Cherney, a nephrologist at the Toronto General Hospital, who contributed to the Canadian Test department, says the results show that it is possible to reduce the loss of the renal function before patients need dialysis or kidney transplant, can be read in the Novo Nodisk company.